Home › Ewing Sarcoma
Pag-aaral pangklinika para sa Ewing Sarcoma na nagre-recruit sa U.S.
34 pag-aaral para sa Ewing Sarcoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY8 pag-aaral
- Houston, TX7 pag-aaral
- Memphis, TN7 pag-aaral
- Philadelphia, PA7 pag-aaral
- Los Angeles, CA6 pag-aaral
- Washington, DC6 pag-aaral
- Aurora, CO6 pag-aaral
- Boston, MA6 pag-aaral
- Birmingham, AL5 pag-aaral
- Atlanta, GA5 pag-aaral
- Cincinnati, OH5 pag-aaral
- Nashville, TN4 pag-aaral
- Gainesville, FL4 pag-aaral
- St. Petersburg, FL4 pag-aaral
- Phoenix, AZ4 pag-aaral
- Dallas, TX4 pag-aaral
- Salt Lake City, UT4 pag-aaral
- Tampa, FL4 pag-aaral
- Baltimore, MD4 pag-aaral
- Columbus, OH4 pag-aaral
- Grand Rapids, MI4 pag-aaral
- Ann Arbor, MI4 pag-aaral
- Hartford, CT3 pag-aaral
- Miami, FL3 pag-aaral
- St. Louis, MO3 pag-aaral
- Harrisburg, PA3 pag-aaral
- The Bronx, NY3 pag-aaral
- Greenburgh, NY3 pag-aaral
- Minneapolis, MN3 pag-aaral
- Orange, CA3 pag-aaral
- Portland, OR3 pag-aaral
- San Francisco, CA3 pag-aaral
Ayos sa estado
- Alabama5 pag-aaral
- Arizona4 pag-aaral
- California12 pag-aaral
- Colorado6 pag-aaral
- Connecticut4 pag-aaral
- District of Columbia6 pag-aaral
- Florida7 pag-aaral
- Georgia5 pag-aaral
- Maryland4 pag-aaral
- Massachusetts6 pag-aaral
- Michigan9 pag-aaral
- Minnesota5 pag-aaral
- Missouri4 pag-aaral
- New Jersey4 pag-aaral
- New York12 pag-aaral
- Ohio9 pag-aaral
- Oregon3 pag-aaral
- Pennsylvania10 pag-aaral
- Tennessee11 pag-aaral
- Texas10 pag-aaral
- Utah4 pag-aaral
- Wisconsin3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06541262A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Nagre-recruitPhase 1
Edad 16 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07197554Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Nagre-recruitPhase 1/2
Edad 2 hanggang 30 · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT05734066Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06395103Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Nagre-recruitPhase 1
Edad 2 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07297979Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Nagre-recruitPhase 1
7 Months – 21 Years · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT02508038XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06571734Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Nagre-recruitPhase 1
12 Months – 20 Years · Lahat ng kasarian · Na-update Okt 8, 2026 · NCT02013336Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Nagre-recruitPhase 2
Edad 0 hanggang 50 · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT07321912Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Nagre-recruit
Edad 2 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT07188532Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Nagre-recruitPhase 1
Edad 1 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07194044Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Nagre-recruitPhase 1
Edad 12 hanggang 85 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT03715933Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Nagre-recruitPhase 1/2
Hanggang edad 26 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06465199Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Nagre-recruitPhase 1
Edad 5 hanggang 40 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06156410Lurbinectedin in FET-Fused Tumors
Nagre-recruitPhase 1/2
Edad 10 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Nagre-recruit
Lahat ng edad · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Nagre-recruitPhase 1
Edad 1 hanggang 23 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT07628634Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Nagre-recruit
Hanggang edad 39 · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06625190Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update May 19, 2026 · NCT04901702B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update May 19, 2026 · NCT04897321Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Nagre-recruitObservasyonal na pag-aaral
Edad 4 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT03442465Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.